HIV/AIDS Vaccine

Interferon resistance gene needed for modified vaccinia virus Ankara replication

Published in AIDS Weekly, August 4th, 2003

by Michael Greer, senior medical writer - Researchers in Germany have identified an interferon (IFN) resistance gene whose expression is critical for modified vaccinia virus Ankara (MVA) replication.

Highly attenuated MVA "serves as a candidate vaccine to immunize against infectious diseases and cancer," including HIV infection, explained Simone Hornemann and colleagues at Ludwig Maximilians University in Munich and the Technical University of Munich.

A mutant form of MVA lacking expression of the IFN resistance gene E3L was unable to replicate in chicken embryo fibroblasts (CEF) used in experimental tissue cultures, Hornemann and coauthors...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2003-08-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry